Vaginal oestrogen therapy after breast cancer: Is it safe?

Riccardo Ponzone, Nicoletta Biglia, Maria Elena Jacomuzzi, Furio Maggiorotto, Luca Mariani, Piero Sismondi

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

The increasing number of breast cancer patients who suffer from menopausal symptoms is mainly due to the extensive use of adjuvant treatments in the younger women. Both short and long-term side effects of oestrogen deficiency may severely impact on the quality of life of these women and should not be underestimated. Hormonal treatments are contraindicated in breast cancer survivors mainly due to the concern that dormant micrometastases may be stimulated to grow. Alternative non-hormonal remedies are now available to alleviate symptoms and to prevent chronic diseases associated with oestrogen deficiency. Urogenital atrophy is an important consequence of oestrogen deprivation that can be effectively treated by vaginal estrogens, although systemic absorption occurs with conventional doses. Preliminary data suggest that much lower doses of vaginal estrogens can alleviate urogenital atrophy without influencing serum estrogenic levels. Further research is warranted to confirm whether vaginal estrogens are safe in symptomatic breast cancer patients who are non-responsive to alternative treatments.

Original languageEnglish
Pages (from-to)2673-2681
Number of pages9
JournalEuropean Journal of Cancer
Volume41
Issue number17
DOIs
Publication statusPublished - Nov 2005

Fingerprint

Estrogens
Breast Neoplasms
Atrophy
Therapeutics
Neoplasm Micrometastasis
Survivors
Chronic Disease
Quality of Life
Serum
Research

Keywords

  • Breast cancer
  • Oestrogen
  • Vaginal

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Vaginal oestrogen therapy after breast cancer : Is it safe? / Ponzone, Riccardo; Biglia, Nicoletta; Jacomuzzi, Maria Elena; Maggiorotto, Furio; Mariani, Luca; Sismondi, Piero.

In: European Journal of Cancer, Vol. 41, No. 17, 11.2005, p. 2673-2681.

Research output: Contribution to journalArticle

Ponzone, Riccardo ; Biglia, Nicoletta ; Jacomuzzi, Maria Elena ; Maggiorotto, Furio ; Mariani, Luca ; Sismondi, Piero. / Vaginal oestrogen therapy after breast cancer : Is it safe?. In: European Journal of Cancer. 2005 ; Vol. 41, No. 17. pp. 2673-2681.
@article{be8bd209063d4f9298f4b2a1c845db85,
title = "Vaginal oestrogen therapy after breast cancer: Is it safe?",
abstract = "The increasing number of breast cancer patients who suffer from menopausal symptoms is mainly due to the extensive use of adjuvant treatments in the younger women. Both short and long-term side effects of oestrogen deficiency may severely impact on the quality of life of these women and should not be underestimated. Hormonal treatments are contraindicated in breast cancer survivors mainly due to the concern that dormant micrometastases may be stimulated to grow. Alternative non-hormonal remedies are now available to alleviate symptoms and to prevent chronic diseases associated with oestrogen deficiency. Urogenital atrophy is an important consequence of oestrogen deprivation that can be effectively treated by vaginal estrogens, although systemic absorption occurs with conventional doses. Preliminary data suggest that much lower doses of vaginal estrogens can alleviate urogenital atrophy without influencing serum estrogenic levels. Further research is warranted to confirm whether vaginal estrogens are safe in symptomatic breast cancer patients who are non-responsive to alternative treatments.",
keywords = "Breast cancer, Oestrogen, Vaginal",
author = "Riccardo Ponzone and Nicoletta Biglia and Jacomuzzi, {Maria Elena} and Furio Maggiorotto and Luca Mariani and Piero Sismondi",
year = "2005",
month = "11",
doi = "10.1016/j.ejca.2005.07.015",
language = "English",
volume = "41",
pages = "2673--2681",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "17",

}

TY - JOUR

T1 - Vaginal oestrogen therapy after breast cancer

T2 - Is it safe?

AU - Ponzone, Riccardo

AU - Biglia, Nicoletta

AU - Jacomuzzi, Maria Elena

AU - Maggiorotto, Furio

AU - Mariani, Luca

AU - Sismondi, Piero

PY - 2005/11

Y1 - 2005/11

N2 - The increasing number of breast cancer patients who suffer from menopausal symptoms is mainly due to the extensive use of adjuvant treatments in the younger women. Both short and long-term side effects of oestrogen deficiency may severely impact on the quality of life of these women and should not be underestimated. Hormonal treatments are contraindicated in breast cancer survivors mainly due to the concern that dormant micrometastases may be stimulated to grow. Alternative non-hormonal remedies are now available to alleviate symptoms and to prevent chronic diseases associated with oestrogen deficiency. Urogenital atrophy is an important consequence of oestrogen deprivation that can be effectively treated by vaginal estrogens, although systemic absorption occurs with conventional doses. Preliminary data suggest that much lower doses of vaginal estrogens can alleviate urogenital atrophy without influencing serum estrogenic levels. Further research is warranted to confirm whether vaginal estrogens are safe in symptomatic breast cancer patients who are non-responsive to alternative treatments.

AB - The increasing number of breast cancer patients who suffer from menopausal symptoms is mainly due to the extensive use of adjuvant treatments in the younger women. Both short and long-term side effects of oestrogen deficiency may severely impact on the quality of life of these women and should not be underestimated. Hormonal treatments are contraindicated in breast cancer survivors mainly due to the concern that dormant micrometastases may be stimulated to grow. Alternative non-hormonal remedies are now available to alleviate symptoms and to prevent chronic diseases associated with oestrogen deficiency. Urogenital atrophy is an important consequence of oestrogen deprivation that can be effectively treated by vaginal estrogens, although systemic absorption occurs with conventional doses. Preliminary data suggest that much lower doses of vaginal estrogens can alleviate urogenital atrophy without influencing serum estrogenic levels. Further research is warranted to confirm whether vaginal estrogens are safe in symptomatic breast cancer patients who are non-responsive to alternative treatments.

KW - Breast cancer

KW - Oestrogen

KW - Vaginal

UR - http://www.scopus.com/inward/record.url?scp=27744597359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744597359&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2005.07.015

DO - 10.1016/j.ejca.2005.07.015

M3 - Article

C2 - 16239103

AN - SCOPUS:27744597359

VL - 41

SP - 2673

EP - 2681

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 17

ER -